Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168001 | 0.84 | AXL (0.54) | METKDR | |
| SCHEMBL12411297 | 0.80 | CSF1R (0.44) | METFGFR2PDGFRAKITGPR119 | |
| SCHEMBL1893954 | 0.80 | IRAK4 (0.46) | METGPR119ALOX5APFEN1NSD2 | |
| SCHEMBL20758445 | 0.79 | GPR119 (0.60) | GPR119ALOX5APFEN1 | |
| SCHEMBL5828984 | 0.79 | EPHA2 (0.50) | KDRNSD2EHMT2 | |
| SCHEMBL371861 | 0.78 | MET (0.51) | METPDGFRAKDR | |
| SCHEMBL5145069 | 0.78 | MET (0.45) | METPDGFRAKDRKIT | |
| SCHEMBL1897146 | 0.77 | IRAK4 (0.44) | METGPR119ALOX5APFEN1 | |
| SCHEMBL12411142 | 0.77 | GPR119 (0.42) | METGPR119ALOX5APFEN1 | |
| SCHEMBL5622929 | 0.77 | NSD2 (0.48) | KDRGPR119NSD2EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| EP-2609091-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | Lead Discovery Center GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, ERBB3 | MET 8/4885FGFR2 88/4885PDGFRA 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.